ProCE Banner Activity

Extended Follow-up and Landmark Analyses From Pivotal Phase II Trial of Glofitamab in R/R LBCL

Conference Coverage
Slideset

Fixed-duration glofitamab demonstrated durable responses in patients with heavily pretreated LBCL, with most in CR at end of treatment remaining in remission.

Released: June 04, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis